Standardising Benefit:Risk Assessment Heads DIA EuroMeeting NewsNeena Brizmohun describes how endeavours by regulators to create standardised frameworks for evaluating the benefits and risks of drugs are progressing and reports on other news from the Drug Information Association's 22nd Annual EuroMeeting in Monaco from 8-10 March.

摘要

Efforts by regulatory agencies around the world to standardise for the first time how they assess the benefits and risks of the drugs they review are advancing. New rules on clinical trial registry and transparency requirements are coming in the European Union and the US. And the creation of a global network for clinical research that would allow industry to share trial data more effectively is gathering momentum.These and other notable regulatory developments were revealed at the Drug Information Association EuroMeeting and are described in detail in the series of articles below.